Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Provectus Biopharmaceuticals Inc PVCT

Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.


OTCQB:PVCT - Post by User

Post by mplauton Nov 11, 2013 6:06pm
291 Views
Post# 21895548

Provectus to Change its Name and Reincorporate in Delaware

Provectus to Change its Name and Reincorporate in DelawareThese moves will have two important effects: 1] The name change will require all shorts to cover before they can short again. 2] Delaware is a much more respectable state to be from than Nevada.
This suggests that PVCT is making the final moves to sell itself.



PVCT PR

Provectus to Hold Special Meeting of Stockholders December 16, 2013, in Knoxville, Tennessee

Tuesday November 5, 2013

Provectus Pharmaceuticals to Change Name to Provectus Biopharmaceuticals, Inc., Reincorporate in Delaware

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, https://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, will hold a special meeting of stockholders to vote on the change of the company's name to Provectus Biopharmaceuticals, Inc. and reincorporation of the Company in the State of Delaware from the State of Nevada. The special meeting of stockholders will be held on December 16, 2013 at 4:00 pm EST at the law offices of Baker, Donelson, Bearman, Caldwell & Berkowitz, PC, which is located at 265 Brookview Centre Way, Suite 600, Knoxville, Tennessee 37819.

Dr. Craig Dees, PhD, CEO of Provectus, said, "We believe that these two proposals demonstrate our commitment to protecting our shareholders' interests and communicating with the markets about our business and our plans for the future.

"Changing our name to 'Provectus Biopharmaceuticals, Inc.' will better communicate to the public the current and future nature of our business operations and enable us to better implement our business plan. The new name, if approved, would not affect our business, operations, reporting requirements or stock price but will require a new CUSIP.

"Reincorporation in Delaware will give us more flexibility, clarity and predictability with respect to our corporate governance. The corporate laws in Delaware are more comprehensive, widely-used and extensively interpreted than those of other states, including Nevada. In addition, Delaware provides a recognized body of corporate law that is consistently interpreted by Delaware courts, which we believe will facilitate corporate governance by our officers and directors."

Bullboard Posts